Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Medtronic
Dow
McKesson
Colorcon
Boehringer Ingelheim

Last Updated: January 17, 2022

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ARGATROBAN IN 0.9% SODIUM CHLORIDE

➤ Subscribe for complete access

« Back to Dashboard

All Clinical Trials for Argatroban In 0.9% Sodium Chloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00035178 ↗ Pharmacokinetics/Pharmacodynamics of Argatroban Injection in End-Stage Renal Disease Patients Undergoing Hemodialysis Completed Texas Biotechnology Corporation Phase 4 2002-05-01 The primary goals of this investigation are to provide guidance on how to dose Argatroban in patients undergoing hemodialysis and to assess the safety and tolerability of Argatroban in hemodialysis patients. The secondary goal of the study will be to assess the adequacy of anticoagulation during hemodialysis.
NCT00039858 ↗ Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin Completed GlaxoSmithKline Phase 4 2003-09-01 The purpose of this study is to evaluate the safe and effective dose of Argatroban for prophylaxis and/or treatment of thrombosis in pediatric patients with current or previous diagnosis of heparin-induced thrombocytopenia (HIT) and thrombosis syndrome (HITTS), or who in the opinion of the investigator require alternative anticoagulation due to an underlying condition.
NCT00039858 ↗ Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin Completed Encysive Pharmaceuticals Phase 4 2003-09-01 The purpose of this study is to evaluate the safe and effective dose of Argatroban for prophylaxis and/or treatment of thrombosis in pediatric patients with current or previous diagnosis of heparin-induced thrombocytopenia (HIT) and thrombosis syndrome (HITTS), or who in the opinion of the investigator require alternative anticoagulation due to an underlying condition.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Argatroban In 0.9% Sodium Chloride

Condition Name

Condition Name for Argatroban In 0.9% Sodium Chloride
Intervention Trials
Ischemic Stroke 3
Heparin-induced Thrombocytopenia 3
Stroke 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Argatroban In 0.9% Sodium Chloride
Intervention Trials
Stroke 9
Thrombocytopenia 8
Ischemic Stroke 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Argatroban In 0.9% Sodium Chloride

Trials by Country

Trials by Country for Argatroban In 0.9% Sodium Chloride
Location Trials
United States 74
Japan 12
China 10
Germany 8
Italy 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Argatroban In 0.9% Sodium Chloride
Location Trials
Texas 6
Massachusetts 4
Minnesota 4
Illinois 4
Ohio 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Argatroban In 0.9% Sodium Chloride

Clinical Trial Phase

Clinical Trial Phase for Argatroban In 0.9% Sodium Chloride
Clinical Trial Phase Trials
Phase 4 14
Phase 3 4
Phase 2 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Argatroban In 0.9% Sodium Chloride
Clinical Trial Phase Trials
Completed 17
Recruiting 6
Terminated 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Argatroban In 0.9% Sodium Chloride

Sponsor Name

Sponsor Name for Argatroban In 0.9% Sodium Chloride
Sponsor Trials
Mitsubishi Tanabe Pharma Corporation 3
The University of Texas Health Science Center, Houston 3
GlaxoSmithKline 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Argatroban In 0.9% Sodium Chloride
Sponsor Trials
Other 26
Industry 11
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
McKinsey
Colorcon
Boehringer Ingelheim
Johnson and Johnson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.